Coherus Advances Biosimilars Model; Inks Daiichi Deal in Asia
By Jennifer Boggs
Tuesday, May 8, 2012
Capitalizing on a wealth of biologics expertise, 2010 start-up Coherus BioSciences Inc. is moving into the global biosimilars space, kicking off its efforts with an Asian partnership with Daiichi Sankyo Co. Ltd. to develop and commercialize biosimilar versions of Enbrel (etanercept, Amgen Inc.) and Rituxan (rituximab, Biogen Idec Inc. and Roche AG).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.